Stage-resolved cytokine profiling nominates IL-17 as a prognostic node in relapsed/refractory B-cell lymphoma.
BACKGROUND B-cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia (B-ALL) are highly heterogeneous malignancies. While immunochemotherapy and CD19 chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of newly diagnosed (ND) and relapsed or refractory (R/R) disease, clin...